Measurement of oral health quality of life among patients who underwent haematopoietic stem-cell transplantation

Abstract

Oral mucositis is a painful condition that occurs in patients who have undergone haematopoietic stem-cell transplantation (HSCT) and has a huge impact on their quality of life. The objective of this study was to examine the extent to which interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-α) are associated with oral health quality of life among patients who underwent HSCT. A. C. Camargo Cancer Center patients were evaluated over 20 months at 4 different time-points: a) at patient admission (M1); b) on the day of infusion of HSC (M2); c) 12 and 20 days after the first day of the conditioning regimen for autologous and allogeneic transplantation, respectively (M3); and d) 30 days after the first day of the conditioning regimen (M4). Mucositis clinical evaluations were performed using World Health Organization (WHO) criteria. Oral health quality of life was measured using the Oral Health Impact Profile short form (OHIP-14), Oral Mucositis Quality of Life (OMQoL) and Patient-Reported Oral Mucositis Symptom (PROMS) scales. Correlations between clinical data and quality of life scores were examined. STATA 11.0 was used to perform the statistical analyses (5% level of significance). Eighty-two patients participated in the study; 62.2% were male, 28.05% had multiple myeloma, and the mean age was 48.49 years (SD 13.76). Higher scores (worse quality of life) were observed as mucositis scores increased, but the results were not significant. The OMQoL had a high correlation with OHIP-14 (0.8377), but the correlation between the PROMS scale and the OHIP-14 was lower (0.6643). Higher concentrations of IL-6 and TNF-α were associated with worse quality of life, according to all indices (p < 0.05). Oral mucositis was associated with quality of life scores (p < 0.01).

Oral health–related quality of life of patients with oral chronic graft-versus-host disease

“…Several studies reported a reduced QoL of cGVHD patients [10,32,33], and correlations between QoL and symptoms of pain and fatigue [18] or xerostomia [16] have been reported as well. In one study among HSCT recipients, patients with extensive cGVHD had on average worse QoL, compared to patients with limited or without cGVHD [34]. In another study among HSCT recipients, of which 33.3% suffered from cGVHD, a reduced QoL was found [35].…”

Effect of Recombinant Human Interleukin-11 on Oral Mucositis Associated with Allogeneic Hematopoietic Stem Cell Transplantation

“…According to the World Health Organization (WHO) Oral mucositis criteria, oral mucosal ulcers are clinically evaluated as grade 0-IV. [7] Grade 0: no abnormality of the oral mucosa; Grade I: Oral mucosa has 1-2 ulcers smaller than 1.0cm, erythema, slightly painful, does not affect eating; Grade II: 1 ulcer larger than 1.0 cm and several small ulcers in the mucosa, painful, the patient can still eat; Grade III: 2 ulcers in the oral mucosa ulcers larger than 1.0 cm and several small ulcers, increased pain, only fluid diet; Grade IV: 2 or more ulcers in the oral mucosa ulcers or fused ulcers larger than 1.0 cm are painful and cannot eat.…”

Kemoterapi ve Radyoterapi Alan Hastalarda Oral Mukozit: Bir Gözden Geçirme

“…Yeterince beslenemeyen hastalarda kilo kaybı, dehidratasyon, mukozada ülserasyon, sıvı-elektrolit dengesizliği gelişebilmekte ve total parenteral beslenme (TPB) başlanabilmektedir (18,25). Sonuçta, hastaların hastanede yatış süreleri uzamakta, tedavi maliyetleri artmakta ve yaşam kaliteleri bozulmaktadır (9,26). Yapılan bir meta-analiz çalışmasında; OM'si olmayan hastaların ortalama hastanede yatış maliyeti KT siklusu başına 3893 dolar iken OM'li hastalar için ortalama hastanede yatış maliyetinin KT siklusu başına 6277 dolar olduğu belirtilmektedir (27).…”